🔗 Share this article

Given that the US proceeds with historic revisions to its immunization schedules, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning COVID-19 shots throughout the global health crisis and has concentrated on alleged deaths following COVID-19 vaccination in her brief tenure at the FDA.

Planned Changes to Pediatric Vaccine Program

Agency leaders were set to announce major changes to the childhood vaccine schedule in December, bringing the US with the Danish national calendar, it is understood – a substantial departure that would put the US out of alignment with many the global community with no evidence for public health gain. The planned update has been delayed until the new year.

Rather than the director of the vaccine center, Høeg is listed to address the audience at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth individual to lead the office this year.

A Shift at the Regulatory Body

This interim role might represent a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US to become more similar to the Danish model, a country with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Qualifications

Høeg has little discernible track record in drug development, oversight or administrative roles, which has been standard for former heads of the CBER. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Former heads of the center would “be deeply familiar with legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who ran the center have had.”

This division has an enormous range of responsibilities at the agency, she stated.

“The public just focuses on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and so forth, and each of these have to be supervised,” she said. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a major administrative component to the job, which supervises more than 5,000 employees. “It is a enormous administrative position, if you perform it correctly,” Woodcock said.

Agency Reaction and Controversial Policies

In response to questions about Høeg’s fitness for the role and whether this selection indicates more teamwork among FDA leaders on immunizations, a spokesperson responded that the “questions are based on flawed assumptions”.

“Her resume aligns with the responsibilities of her job,” the representative stated, citing the months Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s controversial priority voucher program, a controversial expedited drug-approval program that apparently troubled her preceding directors. “How are these medications being picked for this expedited pathway? Who takes the calls?” Howard asked. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, except for shots.”

Documented History on Vaccines

With immunizations, Dr. Høeg has a more established, if concerning, track record, Howard said. She published a study using unverified crowd-sourced reports to estimate the frequency of heart inflammation after Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccinations are riskier than they are.

Part of her “wish list” for the new federal leadership featured altering regulations for recently developed shots and discontinuing “non-essential” vaccines, she remarked after the election on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of excluding teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who begins with her conclusions and works backwards to retrofit the data in a highly deceptive, untruthful way,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|